15 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 5 Not applicable, 4 Phase 2, 3 Phase 4, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 2, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 4 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Flushing: new trials by email Literature Review of Flushing trials Research Report on Flushing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALDH2 Genetic Testing in East Asian Community Genetic Test Results Return, Alcohol Flushing Education - Healthy Adult, Flushing | Not applicable | Not yet recruiting | Northwestern University | 100 | 2026-11-01 | 2026-08-11 |
| Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea Transaricular vagus nerve stimulation (taVNS) - Rosacea, Rosacea, Erythematotelangiectatic | Not applicable | Recruiting | Brigham and Women's Hospital | 10 | 2026-05-23 | 2026-08-14 |
| A Standard Carbon Dioxide Flushing Protocol to Reduce Air Embolization During Thoracic Endovascular Aortic Repair Carbon dioxide pre-implant endograft flushing followed by saline flushing, Saline endograft flushing - Type B Acute Aortic Syndrome, Thoracic and Thoracoabdominal Aneurysms With Crawford Extent I, II, III, or IV | Not applicable | Recruiting | University of Bologna | 90 | 2025-07-15 | 2026-07-29 |
| Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea SCARCr tester 1, Placebo - Rosacea, Redness | Not applicable | Completed | NAOS Argentina S.A. | 70 | 2024-05-16 | 2025-02-28 |
| Treatment of Asian Flushing Syndrome With Topical Alpha Agonists Brimonidine Tartrate, Placebo Vehicle Gel - Flushing, Alcohol-Related Disorders | Early Phase 1 | Completed | University of California, San Francisco | 20 | 2018-07-12 | 2020-05-04 |
| Clinical Pharmacology of Platinum-based Hyperthermic Intraperitoneal Chemotherapy HIPEC with flushing afterwards, HIPEC without flushing afterwards - Peritoneal Carcinomatosis | Completed | Radboud University Medical Center | 20 | 2018-03-01 | 2020-10-20 | |
| Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis dimethyl fumarate, acetylsalicylic acid, ASA-Placebo - Relapsing-Remitting Multiple Sclerosis | Phase 4 | Completed | Biogen | 241 | 2014-05-01 | 2016-12-28 |
| P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Octreotide LAR - Neuroendocrine Carcinoma | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 2 | 2013-12-01 | 2015-01-12 |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Lanreotide, Placebo - Carcinoid Syndrome | Phase 3 | Completed | Ipsen | 115 | 2009-05-01 | 2022-10-14 |
| Role of Prostaglandins on Niacin-Induced Flushing Niacin and aspirin - Flushing | Completed | Eastern Virginia Medical School | 30 | 2009-03-01 | 2010-03-10 | |
| Effects of Psyllium on Niacin Tolerability Psyllium, Aspirin - Flushing, Hyperlipidemias | Phase 4 | Completed | VA Greater Los Angeles Healthcare System | 26 | 2009-03-01 | 2017-12-12 |
| Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH) Quercetin, Placebo - Flushing | Phase 4 | Completed | University of Pennsylvania | 17 | 2009-02-01 | 2015-03-05 |
| Alternative Options to Minimize Niacin-Induced Flushing Apple pectin, Aspirin 325 mg, Placebo - Hypercholesterolemia, Flushing | Not applicable | Completed | Patrick Moriarty, MD, FACP, FACC | 100 | 2009-01-01 | 2014-06-05 |
| A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers GSK256073A tablets + IR niacin tablets - Healthy Subjects, Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 24 | 2007-12-01 | 2012-04-30 |
| Effects of PRK 124 Lotion in Acne Rosacea PRK 124 - Acne Rosacea | Phase 1 / Phase 2 | Completed | University of California, Irvine | 24 | 2007-04-01 | 2014-01-17 |
| Effect of MK0524A on Flushing Caused by Niacin (0524A-056) MK0524A, /Duration of Treatment : 4 Weeks, Comparator : niacin /Duration of Treatment : 1 Weeks - Flushing | Phase 3 | Completed | Merck Sharp & Dohme LLC | 330 | 2007-04-01 | 2017-02-17 |
| MK0524A Phase IIb Study (0524A-011)(COMPLETED) Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks - Flushing | Phase 2 | Completed | Merck Sharp & Dohme LLC | 154 | 2004-08-01 | 2015-08-25 |
| Endpoint Validation Study (0524A-015) MK0524A, /Duration of Treatment : 8 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks - Flushing | Phase 2 | Completed | Merck Sharp & Dohme LLC | 165 | 2004-08-01 | 2017-02-17 |
| Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing Mastocytosis, Anaphylaxis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 100 | 2002-10-01 | 2008-03-04 |
Rosacea (3) · Diarrhea (2) · Erythema (2) · Neuroendocrine Tumors (2) · Telangiectasis (2) · Acne Vulgaris (1) · Alcohol-Related Disorders (1) · Alzheimer Disease (1) · Anaphylaxis (1) · Aneurysm (1) · Carcinoid Tumor (1) · Carcinoma, Neuroendocrine (1) · Cardiovascular Diseases (1) · Dyslipidemias (1)
Pathological Conditions, Signs and Symptoms (19) · Signs and Symptoms (19) · Skin Manifestations (19) · Neoplasms (5) · Cardiovascular Diseases (3) · Neoplasms by Histologic Type (3) · Nervous System Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Vascular Diseases (3) · Adenocarcinoma (2) · Brain Diseases (2) · Carcinoma (2) · Central Nervous System Diseases (2) · Chemically-Induced Disorders (2)
Aspirin (4) · Duration of Therapy (3) · Niacin (2) · Brimonidine Tartrate (1) · Dimethyl Fumarate (1) · Ethanol (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · MK-0524 (1) · Psyllium (1) · Quercetin (1) · isoquercitrin (1) · lanreotide (1) · pyratine 6 (1)
Merck Sharp & Dohme LLC (3) · Biogen (1) · Brigham and Women's Hospital (1) · Eastern Virginia Medical School (1) · GlaxoSmithKline (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Ipsen (1) · NAOS Argentina S.A. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Northwestern University (1) · Patrick Moriarty, MD, FACP, FACC (1) · Radboud University Medical Center (1) · University of Bologna (1) · University of California, Irvine (1) · University of California, San Francisco (1)
United States (12) · Brazil (2) · Argentina (1) · Czechia (1) · India (1) · Ireland (1) · Italy (1) · Latvia (1) · Netherlands (1) · Poland (1) · Russia (1) · Serbia (1) · South Africa (1) · Turkey (Türkiye) (1) · Ukraine (1)
Aaron I Vinik, MD, PhD (1) · Freny V Mody, MD (1) · Gerald D Weinstein, MD (1) · Jennifer L Young, PhD (1) · Jonathan Strosberg, M.D. (1) · Mauro Gargiulo, MD (1) · Patrick Moriarty, MD (1) · Richard L. Dunbar, MD (1) · Wesley Yu, MD (1)
PMID 27214300, PMID 31754316, PMID 31799996, PMID 32594200
K01HL173859 (1)